|
1
|
Frühwald MC, Biegel JA, Bourdeaut F,
Roberts CW and Chi SN: Atypical teratoid/rhabdoid tumors-current
concepts, advances in biology, and potential future therapies.
Neuro Oncol. 18:764–778. 2016. View Article : Google Scholar
|
|
2
|
Hoffman LM, Richa rdson EA, Ho B, Ma rgol
A, Reddy A, Lafay-Cousin L, Chi S, Slavc I, Judkins A, Hasselblatt
M, et al: Advancing biology-based therapeutic approaches for
atypical teratoid rhab tumors. Neuro Oncol. 22:944–954. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chi SN, Zimmerman MA, Yao X, Cohen KJ,
Burger P, Biegel JA, Rorke-Adams LB, Fisher MJ, Janss A, Mazewski
C, et al: Intensive multimodality treatment for children with newly
diagnosed CNS atypical teratoid rhab tumor. J Clin Oncol.
27:385–389. 2009. View Article : Google Scholar
|
|
4
|
Lafay-Cousin L, Fay-McClymont T, Johnston
D, Fryer C, Scheinemann K, Fleming A, Hukin J, Janzen L, Guger S,
Strother D, et al: Neurocognitive evaluation of long term survivors
of atypical teratoid rhab tumors (ATRT): The Canadian registry
experience. Pediatr Blood Cancer. 62:1265–1269. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Biegel JA, Tan L, Zhang F, Wainwright L,
Russo P and Rorke LB: Alterations of the hSNF5/INI1 gene in central
nervous system atypical teratoid/rhabdoid tumors and renal and
extrarenal rhabdoid tumors. Clin Cancer Res. 8:3461–3467.
2002.PubMed/NCBI
|
|
6
|
Biegel JA, Zhou JY, Rorke LB, Stenstrom C,
Wainwright LM and Fogelgren B: Germ-line and acquired mutations of
INI1 in atypical teratoid and rhabdoid tumors. Cancer Res.
59:74–79. 1999.PubMed/NCBI
|
|
7
|
Kadoch C and Crabtree GR: Mammalian
SWI/SNF chromatin remodeling complexes and cancer: Mechanistic
insights gained from human genomics. Sci Adv. 1:e15004472015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Torchia J, Golbourn B, Feng S, Ho KC,
Sin-Chan P, Vasiljevic A, Norman JD, Guilhamon P, Garzia L, Agamez
NR, et al: Integrated (epi)-genomic analyses identify
subgroup-specific therapeutic targets in CNS rhab tumors. Cancer
Cell. 30:891–908. 2016. View Article : Google Scholar
|
|
9
|
Johann PD, Erkek S, Zapatka M, Kerl K,
Buchhalter I, Hovestadt V, Jones DTW, Sturm D, Hermann C, Segura
Wang M, et al: Atypical teratoid/rhab tumors are comprised of three
epigenetic subgroups with distinct enhancer landscapes. Cancer
Cell. 29:379–393. 2016. View Article : Google Scholar
|
|
10
|
Lee RS, Stewart C, Carter SL, Ambrogio L,
Cibulskis K, Sougnez C, Lawrence MS, Auclair D, Mora J, Golub TR,
et al: A remarkably simple genome underlies highly malignant
pediatric rhab cancers. J Clin Invest. 122:2983–2988. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Birks DK, Donson AM, Patel PR, Dunham C,
Muscat A, Algar EM, Ashley DM, Kleinschmidt-Demasters BK, Vibhakar
R, Handler MH and Foreman NK: High expression of BMP pathway genes
distinguishes a subset of atypical teratoid/rhabdoid tumors
associated with shorter survival. Neuro Oncol. 13:1296–1307. 2011.
View Article : Google Scholar
|
|
12
|
Ho B, Johann PD, Grabovska Y, De Dieu
Andrianteranagna MJ, Yao F, Frühwald M, Hasselblatt M, Bourdeaut F,
Williamson D, Huang A and Kool M: Molecular subgrouping of atypical
teratoid/rhabdoid tumors-a reinvestigation and current consensus.
Neuro Oncol. 22:613–624. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Theruvath J, Sotillo E, Mount CW, Graef
CM, Delaidelli A, Heitzeneder S, Labanieh L, Dhingra S, Leruste A,
Majzner RG, et al: Locoregionally administered B7-H3-targeted CAR T
cells for treatment of atypical teratoid/rhab tumors. Nat Med.
26:712–719. 2020. View Article : Google Scholar
|
|
14
|
Birks DK, Donson AM, Patel PR, Sufit A,
Algar EM, Dunham C, Kleinschmidt-DeMasters BK, Handler MH, Vibhakar
R and Foreman NK: Pediatric rhabdoid tumors of kidney and brain
show many differences in gene expression but share dysregulation of
cell cycle and epigenetic effector genes. Pediatr Blood Cancer.
60:1095–1102. 2013. View Article : Google Scholar
|
|
15
|
Wade M, Li YC and Wahl GM: MDM2, MDMX and
p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 13:83–96.
2013. View Article : Google Scholar
|
|
16
|
Tovar C, Graves B, Packman K, Filipovic Z,
Higgins B, Xia M, Tardell C, Garrido R, Lee E, Kolinsky K, et al:
MDM2 small-molecule antagonist RG7112 activates p53 signaling and
regresses human tumors in preclinical cancer models. Cancer Res.
73:2587–2597. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shangary S and Wang S: Small-molecule
inhibitors of the MDM2-p53 protein-protein interaction to
reactivate p53 function: A novel approach for cancer therapy. Annu
Rev Pharmacol Toxicol. 49:223–241. 2009. View Article : Google Scholar
|
|
18
|
Vassilev LT, Vu BT, Graves B, Carvajal D,
Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et
al: In vivo activation of the p53 pathway by small-molecule
antagonists of MDM2. Science. 303:844–848. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J,
Ross TM, Chu XJ, Bartkovitz D, Podlaski F, Janson C, et al:
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in
clinical development. J Med Chem. 56:5979–5983. 2013. View Article : Google Scholar
|
|
20
|
Chen L, Rousseau RF, Middleton SA, Nichols
GL, Newell DR, Lunec J and Tweddle DA: Pre-clinical evaluation of
the MDM2-p53 antagonist RG7388 alone and in combination with
chemotherapy in neuroblastoma. Oncotarget. 6:10207–10221. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lakoma A, Barbieri E, Agarwal S, Jackson
J, Chen Z, Kim Y, McVay M, Shohet JM and Kim ES: The MDM2
small-molecule inhibitor RG7388 leads to potent tumor inhibition in
p53 wild-type neuroblastoma. Cell Death Discov. 1:150262015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Howard TP, Arnoff TE, Song MR, Giacomelli
AO, Wang X, Hong AL, Dharia NV, Wang S, Vazquez F, Pham MT, et al:
MDM2 and MDM4 Are therapeutic vulnerabilities in malignant rhab
tumors. Cancer Res. 79:2404–2414. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carugo A, Minelli R, Sapio L, Soeung M,
Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, et
al: p53 is a master regulator of proteostasis in SMARCB1-deficient
malignant rhab tumors. Cancer Cell. 35:204–220.e9. 2019. View Article : Google Scholar
|
|
24
|
Alimova I, Pierce AM, Harris P, Donson A,
Birks DK, Prince E, Balakrishnan I, Foreman NK, Kool M, Hoffman L,
et al: Targeting Polo-like kinase 1 in SMARCB1 deleted atypical
teratoid rhab tumor. Oncotarget. 8:97290–97303. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alimova I, Pierce A, Danis E, Donson A,
Birks DK, Griesinger A, Foreman NK, Santi M, Soucek L, Venkataraman
S and Vibhakar R: Inhibition of MYC attenuates tumor cell
self-renewal and promotes senescence in SMARCB1-deficient group 2
atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
Int J Cancer. 144:1983–1995. 2019. View Article : Google Scholar
|
|
26
|
Tang Y, Gholamin S, Schubert S, Willardson
MI, Lee A, Bandopadhayay P, Bergthold G, Masoud S, Nguyen B, Vue N,
et al: Epigenetic targeting of Hedgehog pathway transcriptional
output through BET bromodomain inhibition. Nat Med. 20:732–740.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Balakrishnan I, Danis E, Pierce A,
Madhavan K, Wang D, Dahl N, Sanford B, Birks DK, Davidson N,
Metselaar DS, et al: Senescence induced by BMI1 inhibition is a
therapeutic vulnerability in H3K27M-mutant DIPG. Cell Rep.
33:1082862020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: affy-analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dai M, Wang P, Boyd AD, Kostov G, Athey B,
Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, et al: Evolving
gene/transcript definitions significantly alter the interpretation
of GeneChip data. Nucleic Acids Res. 33:e1752005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kauffmann A, Gentleman R and Huber W:
arrayQualityMetrics-a bioconductor package for quality assessment
of microarray data. Bioinformatics. 25:415–416. 2009. View Article : Google Scholar
|
|
31
|
Irizarry RA, Hobbs B, Collin F,
Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP:
Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics. 4:249–264.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang D, Pierce A, Veo B, Fosmire S, Danis
E, Donson A, Venkataraman S and Vibhakar R: A regulatory loop of
FBXW7-MYC-PLK1 controls tumorigenesis of MYC-driven
medulloblastoma. Cancers (Basel). 13. pp. 3872021, View Article : Google Scholar
|
|
33
|
Alimova I, Ng J, Harris P, Birks D, Donson
A, Taylor MD, Foreman NK, Venkataraman S and Vibhakar R: MPS1
kinase as a potential therapeutic target in medulloblastoma. Oncol
Rep. 36:2633–2640. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kauffman ME, Kauffman MK, Traore K, Zhu H,
Trush MA, Jia Z and Li YR: MitoSOX-based flow cytometry for
detecting mitochondrial ROS. React Oxyg Species (Apex). 2:361–370.
2016.
|
|
35
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The cancer cell line encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Buscariollo DL, Park HS, Roberts KB and Yu
JB: Survival outcomes in atypical teratoid rhabdoid tumor for
patients undergoing radiotherapy in a surveillance, epidemiology,
and end results analysis. Cancer. 118:4212–4219. 2012. View Article : Google Scholar
|
|
37
|
Rorke LB, Packer RJ and Biegel JA: Central
nervous system atypical teratoid/rhabdoid tumors of infancy and
childhood: Definition of an entity. J Neurosurg. 85:56–65. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang X, Lee RS, Alver BH, Haswell JR, Wang
S, Mieczkowski J, Drier Y, Gillespie SM, Archer TC, Wu JN, et al:
SMARCB1-mediated SWI/SNF complex function is essential for enhancer
regulation. Nat Genet. 49:289–295. 2017. View Article : Google Scholar :
|
|
39
|
Nakayama RT, Pulice JL, Valencia AM,
McBride MJ, McKenzie ZM, Gillespie MA, Ku WL, Teng M, Cui K,
Williams RT, et al: SMARCB1 is required for widespread BAF
complex-mediated activation of enhancers and bivalent promoters.
Nat Genet. 49:1613–1623. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Berberich A, Kessler T, Thomé CM, Pusch S,
Hielscher T, Sahm F, Oezen I, Schmitt LM, Ciprut S, Hucke N, et al:
Targeting resistance against the MDM2 inhibitor RG7388 in
glioblastoma cells by the MEK inhibitor trametinib. Clin Cancer
Res. 25:253–265. 2019. View Article : Google Scholar
|
|
41
|
Mai WX, Gosa L, Daniels VW, Ta L, Tsang
JE, Higgins B, Gilmore WB, Bayley NA, Harati MD, Lee JT, et al:
Cytoplasmic p53 couples oncogene-driven glucose metabolism to
apoptosis and is a therapeutic target in glioblastoma. Nat Med.
23:1342–1351. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Konopleva M, Martinelli G, Daver N,
Papayannidis C, Wei A, Higgins B, Ott M, Mascarenhas J and Andreeff
M: MDM2 inhibition: An important step forward in cancer therapy.
Leukemia. 34:2858–2874. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Carol H, Reynolds CP, Kang MH, Keir ST,
Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT,
et al: Initial testing of the MDM2 inhibitor RG7112 by the
pediatric preclinical testing program. Pediatr Blood Cancer.
60:633–641. 2013. View Article : Google Scholar
|
